Condition: Hepato Cellular Carcinoma (HCC) · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
The purpose of this study is to evaluate whether fecal microbiota transplantation (FMT), when administered in combination with atezolizumab and bevacizumab, can improve treatment response in participants with hepatocellular carcinoma (HCC) whose disease has progressed during prior atezolizumab-bevacizumab therapy. The study will also assess the safety and feasibility of this treatment strategy. Primary Objective: To determine whether FMT can restore or enhance response to atezolizumab and bevacizumab following disease progression. Participants will: Receive a fecal microbiota transplantation (FMT). Resume treatment with atezolizumab and bevacizumab, administered every 3 weeks.
This description comes directly from the study's public registry record.
Fabio Piscaglia, MD · 0512142214 · fabio.piscaglia@unibo.it
Mariarosaria Marseglia Biologist, Biologist · mariarosaria.marseglia@aosp.bo.it
Always discuss trial participation with your own doctor first.
| IRCCS AOU di Bologna Policlinico di Sant'Orsola | Bologna, BO, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07276100